Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Income from Continuing Operations (2010 - 2026)

Lite Strategy (LITS) posted Income from Continuing Operations of -$21.6 million for Q1 2026, up 27.68% on a QoQ basis from -$29.8 million in Q4 2025, and down 738.1% year-over-year from $3.4 million in Q1 2025.

Analysis

Lite Strategy (LITS) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Lite Strategy has reported Income from Continuing Operations for 17 years, with the latest figure at -$21.6 million in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 738.1% year-over-year to -$21.6 million in Q1 2026; TTM through Mar 2026 was -$57.7 million, a 79.65% decrease from a year earlier, with the FY2025 full-year figure at -$16.4 million, down 192.2% from the prior year.
  • Income from Continuing Operations was -$21.6 million for Q1 2026 at Lite Strategy, up from -$29.8 million in the prior quarter.
  • The five-year high for Income from Continuing Operations was $56.4 million in Q3 2023, with the low at -$29.8 million in Q4 2025.
  • Average Income from Continuing Operations over 5 years is -$7.3 million, with a median of -$10.0 million recorded in 2023.
  • The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations soared 417.8% in 2023, then tumbled 839.69% in 2025.
  • Over 5 years, Income from Continuing Operations stood at $9.8 million in 2022, then sank by 213.2% to -$11.1 million in 2023, then jumped by 71.32% to -$3.2 million in 2024, then sank by 839.69% to -$29.8 million in 2025, then rose by 27.68% to -$21.6 million in 2026.
  • The last three Income from Continuing Operations figures came in at -$21.6 million (Q1 2026), -$29.8 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 601.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -290.61 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - -21.56 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -21.56 Mn
Dec 31, 2025 -29.81 Mn
Sep 30, 2025 -3.64 Mn
Jun 30, 2025 -2.69 Mn
Mar 31, 2025 -2.57 Mn
Dec 31, 2024 -3.17 Mn
Sep 30, 2024 -8.00 Mn
Jun 30, 2024 -18.37 Mn
Mar 31, 2024 -9.12 Mn
Dec 31, 2023 -11.06 Mn
Sep 30, 2023 56.38 Mn
Jun 30, 2023 -10.02 Mn
Mar 31, 2023 -15.43 Mn
Dec 31, 2022 9.77 Mn
Sep 30, 2022 -17.74 Mn
Jun 30, 2022 -15.99 Mn
Mar 31, 2022 -21.50 Mn
Dec 31, 2021 -17.61 Mn
Sep 30, 2021 -20.10 Mn
Jun 30, 2021 -15.46 Mn